Medical Condition News

RSS

ASGE and TV actor encourage African-Americans to undergo screening for colon cancer

CSI: New York actor Hill Harper has joined forces with the American Society for Gastrointestinal Endoscopy (ASGE), representing doctors who specialize in endoscopy and colon cancer screening, in a new Public Service Announcement (PSA) to encourage African-Americans to undergo screening for colon cancer

3 Mar 2010

Informative workshop on multiple sclerosis

Physicians, nurses, and physician assistants in the Portland, Oregon, area who treat and care for patients with multiple sclerosis (MS) are invited to attend "Recognizing and Treating Multiple Sclerosis in the Primary Care Setting," an informative free CME/CE half-day lecture and workshop.

3 Mar 2010

China's SFDA approves Sunridge International's PNT treatment for glaucoma and ocular hypertension

Sunridge International, announced today that China's State Food and Drug Administration, (SFDA), had approved the firm's Pneumatic Trabeculoplasty (PNT) treatment in China.

3 Mar 2010

Geron highlights telomerase inhibitor's activity against cancer stem cells at AACR Special Conference

Geron Corporation today announced several presentations at the American Association for Cancer Research Special Conference on The Role of Telomeres and Telomerase in Cancer Research held in Fort Worth, TX between February 27th and March 1st.

3 Mar 2010

Soluble fiber in oats, apples and nuts reduces inflammation; strengthens immune system

A new University of Illinois study touts the benefits of soluble fiber-found in oats, apples, and nuts, for starters-saying that it reduces the inflammation associated with obesity-related diseases and strengthens the immune system.

3 Mar 2010

Scientists uncover vital clue that could steer research into nervous system disorders

Scientists at the Queensland Brain Institute have uncovered a vital clue into how the brain is wired, which could eventually steer research into nervous system disorders such as Parkinson's disease and cognitive disorders including autism.

3 Mar 2010

Phase III study results of Merck's allergy immunotherapy tablet

In new data from a Phase III study in 345 children and adolescents (ages 5-17 years), patients with grass pollen allergic rhinoconjunctivitis treated with Merck's investigational sublingual grass (Phleum Pratense) allergy immunotherapy tablet (AIT) showed a 26 percent greater improvement in the total combined score (daily symptom score and daily medication score), compared to patients receiving placebo

3 Mar 2010

Impax Laboratories' generic FLOMAX ANDA: FDA grants final approval

Impax Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company’s Abbreviated New Drug Application (ANDA) for the generic version of FLOMAX® (tamsulosin hydrochloride) 0.4mg capsules. The Company also announced that it is commencing shipment through Global Pharmaceuticals, Impax’s generic division.

3 Mar 2010

EMA accepts the filing of Lux Biosciences' MAA for Luveniq

Lux Biosciences, Inc. today announced that the European Medicines Agency has accepted the filing of the company’s Marketing Authorization Application (MAA) for the company’s lead product, Luveniq™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.

3 Mar 2010

Advanced Cell Technology’s MA09-hRPE cells for treatment of SMD: FDA grants orphan drug designation

Advanced Cell Technology, Inc., a biotechnology company applying cellular technology in the field of regenerative medicine, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company’s MA09-hRPE cells for use in the treatment of Stargardt’s Macular Dystrophy (SMD). As a result, the company is eligible to receive a number of benefits, including tax credits, access to grant funding for clinical trials, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of as long as seven years.

3 Mar 2010

Study shows cryoablation technique offers a potential treatment for breast cancer

Freezing a cancer kills it in its place, and also appears to generate an immune response that helps stop the cancer's spread, leading to improved survival rates over surgery, according to a new study in mice from researchers at the University of Michigan Comprehensive Cancer Center.

3 Mar 2010

Study: Patients with community-acquired pneumonia who develop AKI more likely to die after discharge

Patients hospitalized with even mild to moderate community-acquired pneumonia who develop acute kidney injury (AKI) are more likely to die after discharge than pneumonia patients whose kidneys remain healthy, according to a University of Pittsburgh School of Medicine study in the February issue of Kidney International.

3 Mar 2010

Drinking coffee may lower risk of hospitalization for heart rhythm disturbances

Coffee drinkers may be less likely to be hospitalized for heart rhythm disturbances, according to a new study by the Kaiser Permanente Division of Research in Oakland, Calif. The researchers, who note the findings may be surprising because patients frequently report palpitations after drinking coffee, are presenting the study at the American Heart Association's 50th Annual Conference on Cardiovascular Disease Epidemiology and Prevention in San Francisco on March 5, 2010.

3 Mar 2010

Combination of two targeted therapies effective against subset of gastric cancers: Study

A combination of two targeted therapies already shown to be effective in breast cancer packs an effective one-two punch against a subset of gastric cancers that have a specific genetic mutation, a study at UCLA's Jonsson Comprehensive Cancer Center has found.

3 Mar 2010

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance on monoclonal antibody ICT-69 which targets multiple myeloma and ovarian cancers. The antibody has demonstrated high specificity to these cancers by targeting a novel cell surface antigen.

2 Mar 2010

Concerns about unnecessary scans and radiation risk prompt reviews by doctors

Business Week reports on a study that finds 1 in 4 MRI and CT scans are inappropriately recommended by doctors. The study appears in the March issue of the Journal of the American College of Radiology. The researchers analyzed 459 scans at Harborview Medical Center in Seattle.

2 Mar 2010

Antares Pharma completes enrollment in Phase 3 clinical trial of Anturol for OAB

Antares Pharma, Inc. announced today that it has completed enrollment in the double-blind portion of the Company’s Phase 3 clinical trial of Anturol™, its transdermal oxybutynin ATD™ gel for the treatment of overactive bladder (OAB). Top line data from this pivotal trial, which is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA), is expected in the third quarter of this year.

2 Mar 2010

National Cancer Institute awards PDS Biotechnology $1.28M phase 2 SBIR contract

PDS Biotechnology Corporation today announced that the company has been awarded a $1.28M phase 2 SBIR contract by the National Cancer Institute division of the US National Institutes of Health. The contract provides funding to complete studies required to file an Investigational New Drug Application (IND) with the FDA for the company's lead human papillomavirus (HPV)-cancer product late in 2010.

2 Mar 2010

Critical follow-up evaluations provide opportunity to help physicians best evaluate their HF patients

Heart failure is by far the most prevalent chronic cardiac condition. Around 30 million people in Europe have heart failure and its incidence is still increasing: more cases are being identified, more people are living to an old age, and more are surviving a heart attack but with damage to the heart muscle.

2 Mar 2010

InterMune seeks European marketing approval for pirfenidone

InterMune, Inc. today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval to market pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF) in the European Union (EU). Currently, there are no EMA-approved treatments for IPF in the EU.

2 Mar 2010

Medical Condition News

ASGE and TV actor encourage African-Americans to undergo screening for colon cancer

Informative workshop on multiple sclerosis

China's SFDA approves Sunridge International's PNT treatment for glaucoma and ocular hypertension

Geron highlights telomerase inhibitor's activity against cancer stem cells at AACR Special Conference

Soluble fiber in oats, apples and nuts reduces inflammation; strengthens immune system

Scientists uncover vital clue that could steer research into nervous system disorders

Phase III study results of Merck's allergy immunotherapy tablet

Impax Laboratories' generic FLOMAX ANDA: FDA grants final approval

EMA accepts the filing of Lux Biosciences' MAA for Luveniq

Advanced Cell Technology’s MA09-hRPE cells for treatment of SMD: FDA grants orphan drug designation

Study shows cryoablation technique offers a potential treatment for breast cancer

Study: Patients with community-acquired pneumonia who develop AKI more likely to die after discharge

Drinking coffee may lower risk of hospitalization for heart rhythm disturbances

Combination of two targeted therapies effective against subset of gastric cancers: Study

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

Concerns about unnecessary scans and radiation risk prompt reviews by doctors

Antares Pharma completes enrollment in Phase 3 clinical trial of Anturol for OAB

National Cancer Institute awards PDS Biotechnology $1.28M phase 2 SBIR contract

Critical follow-up evaluations provide opportunity to help physicians best evaluate their HF patients

InterMune seeks European marketing approval for pirfenidone

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News